Henry Schein, Inc. $HSIC Shares Bought by M.D. Sass LLC

M.D. Sass LLC raised its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 21.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,314,603 shares of the company’s stock after purchasing an additional 230,407 shares during the period. Henry Schein accounts for 7.1% of M.D. Sass LLC’s portfolio, making the stock its largest holding. M.D. Sass LLC owned 1.08% of Henry Schein worth $87,250,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in HSIC. Artisan Partners Limited Partnership raised its stake in Henry Schein by 0.9% during the 2nd quarter. Artisan Partners Limited Partnership now owns 6,462,204 shares of the company’s stock valued at $472,064,000 after purchasing an additional 55,653 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after buying an additional 2,199,695 shares in the last quarter. Schroder Investment Management Group increased its stake in shares of Henry Schein by 149.3% in the second quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after buying an additional 936,471 shares in the last quarter. Swedbank AB increased its holdings in shares of Henry Schein by 12.4% in the third quarter. Swedbank AB now owns 1,299,571 shares of the company’s stock valued at $86,253,000 after purchasing an additional 143,173 shares in the last quarter. Finally, Norges Bank acquired a new stake in Henry Schein in the second quarter worth about $89,476,000. 96.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wells Fargo & Company boosted their target price on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Barrington Research set a $79.00 price target on Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Barclays started coverage on Henry Schein in a report on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective on the stock. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Morgan Stanley lifted their price target on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research note on Wednesday, November 5th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $76.42.

Henry Schein Trading Up 2.3%

HSIC stock opened at $77.00 on Friday. The company’s 50-day simple moving average is $76.29 and its 200 day simple moving average is $70.94. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.38. The company has a market capitalization of $9.06 billion, a PE ratio of 24.37, a price-to-earnings-growth ratio of 2.24 and a beta of 0.88. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. The company had revenue of $3.34 billion during the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. As a group, sell-side analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.